Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma
Morgane Morabito1,2,3,4,5, Magalie Larcher1,2,3,4,5, Florence Mg Cavalli6,7
1Institut Curie, Orsay, France.
Abstract:
Medulloblastoma (MB) is a pediatric tumor of the cerebellum divided into four groups. Group 3 is of bad prognosis and remains poorly characterized. While the current treatment involving surgery, radiotherapy, and chemotherapy often fails, no alternative therapy is yet available. Few recurrent genomic alterations that can be therapeutically targeted have been identified. Amplifications of receptors of the TGFβ/Activin pathway occur at very low frequency in Group 3 MB. However, neither their functional relevance nor activation of the downstream signaling pathway has been studied. We showed that this pathway is activated in Group 3 MB with some samples showing a very strong activation. Beside genetic alterations, we demonstrated that an ActivinB autocrine stimulation is responsible for pathway activation in a subset of Group 3 MB characterized by high PMEPA1 levels. Importantly, Galunisertib, a kinase inhibitor of the cognate receptors currently tested in clinical trials for Glioblastoma patients, showed efficacy on orthotopically grafted MB-PDX. Our data demonstrate that the TGFβ/Activin pathway is active in a subset of Group 3 MB and can be therapeutically targeted.
Insights
Group 3 medulloblastoma (MB), a pediatric brain tumor, shows activated TGFβ/Activin signaling. Targeting this pathway with Galunisertib showed promise in preclinical models, offering a potential new therapy for this aggressive cancer.
Area of Science:
- Pediatric Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- Medulloblastoma (MB) is a common pediatric brain tumor with distinct molecular subgroups.
- Group 3 MB has a poor prognosis and limited therapeutic options.
- The TGFβ/Activin pathway's role in Group 3 MB is poorly understood.
Purpose of the Study:
- To investigate the activation and functional relevance of the TGFβ/Activin pathway in Group 3 MB.
- To explore therapeutic targeting of this pathway in preclinical models.
Main Methods:
- Analysis of pathway activation in Group 3 MB patient samples.
- Investigation of autocrine ActivinB stimulation.
- Testing the efficacy of Galunisertib in orthotopic medulloblastoma patient-derived xenograft (PDX) models.
Main Results:
- The TGFβ/Activin pathway is activated in a subset of Group 3 MB.
- Autocrine ActivinB stimulation drives pathway activation in tumors with high PMEPA1 levels.
- Galunisertib demonstrated efficacy in preclinical MB models.
Conclusions:
- The TGFβ/Activin pathway is a relevant target in Group 3 MB.
- Galunisertib represents a potential therapeutic strategy for targeting this pathway in medulloblastoma.
Related Concept Videos
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
What is Cell Signaling?
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Endocrine Signaling
Bacterial Signaling

